PHATHOM PHARMACEUTICALS INC. - COMMON STOCK

Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD

26 Sep 2023 07:01:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

05 Sep 2023 07:00:01 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application

21 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports Second Quarter 2023 Results

10 Aug 2023 07:01:28 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD

12 Jun 2023 07:01:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

09 Jun 2023 15:01:22 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

01 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock

23 May 2023 18:41:15 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock

23 May 2023 15:01:12 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA

23 May 2023 15:00:40 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports First Quarter 2023 Results

10 May 2023 07:00:01 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023

09 May 2023 07:00:15 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch

04 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

28 Feb 2023 07:00:03 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Provides Regulatory Updates

09 Feb 2023 15:01:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)

08 Jan 2023 17:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis

03 Jan 2023 15:01:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates

08 Nov 2022 16:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences

03 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement

01 Nov 2022 07:00:02 By Nasdaq GlobeNewswire